Cargando…
Pre-clinical studies of EC2629, a highly potent folate- receptor-targeted DNA crosslinking agent
Folate receptor (FR)-targeted small molecule drug conjugates (SMDCs) have shown promising results in early stage clinical trials with microtubule destabilizing agents, such as vintafolide and EC1456. In our effort to develop FR-targeted SMDCs with varying mechanisms of action, we synthesized EC2629,...
Autores principales: | , , , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7391724/ https://www.ncbi.nlm.nih.gov/pubmed/32728172 http://dx.doi.org/10.1038/s41598-020-69682-9 |